Overactive Bladder - Pipeline Review, H1 2020

April 2020 | 127 pages | ID: O3DBE4C31E1EN
Global Markets Direct

Abstracts

Overactive Bladder - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides an overview of the Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline landscape.

Overactive bladder is a problem with bladder-storage function that causes a sudden urge to urinate. The urge may be difficult to stop, and overactive bladder may lead to the involuntary loss of urine (incontinence). Symptoms include feel a sudden urge to urinate that's difficult to control, experience urge incontinence and awaken two or more times in the night to urinate. Treatment includes change in life style and medications that relax the bladder can be effective for relieving symptoms of overactive bladder and reducing episodes of urge incontinence.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Overactive Bladder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Overactive Bladder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 8, 3, 12, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Overactive Bladder (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Overactive Bladder (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Overactive Bladder (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Overactive Bladder (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Overactive Bladder (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Overactive Bladder - Overview
Overactive Bladder - Therapeutics Development
Overactive Bladder - Therapeutics Assessment
Overactive Bladder - Companies Involved in Therapeutics Development
Overactive Bladder - Drug Profiles
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Overactive Bladder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Overactive Bladder - Pipeline by Aetas Pharma Co Ltd, H1 2020
Overactive Bladder - Pipeline by Allergan Plc, H1 2020
Overactive Bladder - Pipeline by Astellas Pharma Inc, H1 2020
Overactive Bladder - Pipeline by DelNova Inc, H1 2020
Overactive Bladder - Pipeline by Dompe Farmaceutici SpA, H1 2020
Overactive Bladder - Pipeline by Dong-A ST Co Ltd, H1 2020
Overactive Bladder - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020
Overactive Bladder - Pipeline by Evestra Inc, H1 2020
Overactive Bladder - Pipeline by Exxel Pharma Inc, H1 2020
Overactive Bladder - Pipeline by FemmePharma Global Healthcare Inc, H1 2020
Overactive Bladder - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Overactive Bladder - Pipeline by Hydra Biosciences Inc, H1 2020
Overactive Bladder - Pipeline by Imbrium Therapeutics LP, H1 2020
Overactive Bladder - Pipeline by Ion Channel Innovations LLC, H1 2020
Overactive Bladder - Pipeline by J2H Biotech, H1 2020
Overactive Bladder - Pipeline by Johnson & Johnson, H1 2020
Overactive Bladder - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2020
Overactive Bladder - Pipeline by Korea United Pharm Inc, H1 2020
Overactive Bladder - Pipeline by KYORIN Holdings Inc, H1 2020
Overactive Bladder - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
Overactive Bladder - Pipeline by Lipella Pharmaceuticals Inc, H1 2020
Overactive Bladder - Pipeline by Medytox Inc, H1 2020
Overactive Bladder - Pipeline by Merck & Co Inc, H1 2020
Overactive Bladder - Pipeline by Mezzion Pharma Co Ltd, H1 2020
Overactive Bladder - Pipeline by Recordati SpA, H1 2020
Overactive Bladder - Pipeline by Revance Therapeutics Inc, H1 2020
Overactive Bladder - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2020
Overactive Bladder - Pipeline by TheraVida Inc, H1 2020
Overactive Bladder - Pipeline by Velicept Therapeutics Inc, H1 2020
Overactive Bladder - Pipeline by XuanZhu Pharma Co Ltd, H1 2020
Overactive Bladder - Dormant Projects, H1 2020
Overactive Bladder - Dormant Projects, H1 2020 (Contd..1), H1 2020
Overactive Bladder - Dormant Projects, H1 2020 (Contd..2), H1 2020
Overactive Bladder - Dormant Projects, H1 2020 (Contd..3), H1 2020
Overactive Bladder - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Overactive Bladder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Aetas Pharma Co Ltd
Allergan Plc
Astellas Pharma Inc
DelNova Inc
Dompe Farmaceutici SpA
Dong-A ST Co Ltd
DongKoo Bio & Pharma Co Ltd
Evestra Inc
Exxel Pharma Inc
FemmePharma Global Healthcare Inc
Hanmi Pharmaceuticals Co Ltd
Hydra Biosciences Inc
Imbrium Therapeutics LP
Ion Channel Innovations LLC
J2H Biotech
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
Korea United Pharm Inc
KYORIN Holdings Inc
Kyorin Pharmaceutical Co Ltd
Lipella Pharmaceuticals Inc
Medytox Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Recordati SpA
Revance Therapeutics Inc
Taiho Pharmaceutical Co Ltd
TheraVida Inc
Velicept Therapeutics Inc
XuanZhu Pharma Co Ltd